For autoimmune conditions like systemic lupus erythematosus, cellular immunotherapies such as CD19‐targeted Chimeric Antigen Receptor (CAR) T cells are being explored to redirect immune cells and correct underlying autoimmunity by selectively eliminating pathogenic B cells, aiming for potential single‐administration cures [130, 131]. This evidence concerns the gene CD19 and systemic lupus erythematosus.